Clinical Trial

The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this research is to investigate the effects of ripasudil administered as an ophthalmic solution in patients with FED after femtosecond laser assisted cataract surgery. The secondary aim is to identity the characteristics of patients who will benefit the most with the use of ripasudil based on the test results obtained from this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-15.
Trial Details
NCT Number NCT06048380
Lead Sponsor Singapore Eye Research Institute
Conditions Fuchs' Endothelial Dystrophy, Cataract
Enrollment 120 participants
Start Date 2025-03-01
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-01-29